Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
-
General14 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News23 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General14 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News19 hours agoBrisbane rising on global rankings, but still behind southern capitals